Long-term Lung Function and Disease Progression in Children With Early Onset Primary Ciliary Dyskinesia Lung Disease

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Margaret Leigh, MD, University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier:
NCT00722878
First received: July 24, 2008
Last updated: February 5, 2014
Last verified: February 2014

July 24, 2008
February 5, 2014
July 2008
July 2015   (final data collection date for primary outcome measure)
  • Infant lung function [ Time Frame: Measured at initial study visit (for children under 3) ] [ Designated as safety issue: No ]
  • Spirometry measures [ Time Frame: Measured yearly for 5 years (after age of 3 years) ] [ Designated as safety issue: No ]
  • Respiratory cultures [ Time Frame: Measured yearly for 5 years ] [ Designated as safety issue: No ]
  • Chest CT scan results [ Time Frame: Measured at the initial study visit and at Years 3 and 5 ] [ Designated as safety issue: No ]
Infant lung function [ Time Frame: Measured yearly for 5 years ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00722878 on ClinicalTrials.gov Archive Site
Not Provided
  • Spirometry measures [ Time Frame: Measured yearly for 5 years ] [ Designated as safety issue: No ]
  • Certain respiratory cultures [ Time Frame: Measured yearly for 5 years ] [ Designated as safety issue: No ]
  • Chest CT scan results [ Time Frame: Measured at the initial visit and at Years 3 and 5 ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Long-term Lung Function and Disease Progression in Children With Early Onset Primary Ciliary Dyskinesia Lung Disease
Early Onset and Progression of Primary Ciliary Dyskinesia Lung Disease Prior to 10 Years of Age

Primary ciliary dyskinesia (PCD), also known as Kartagener syndrome, is a genetic disorder of the cilia, which are microscopic hair-like cells. Cilia work to keep the respiratory system clean by moving mucus that contains debris to the large airways, where it can be coughed out. People with PCD have cilia that do not move properly and therefore are not effective in cleaning the respiratory system. This study will determine when PCD starts and how it changes over time, specifically in terms of how well the lungs work, what germs grow in lung secretions, and how the lungs look on computed tomography (CT) scans.

PCD, or Kartagener syndrome, is a genetic disorder that causes hair-like cells called cilia to move improperly, or in some cases, not at all. Cilia are needed to help clear the respiratory system of pollutants. When they work properly, they move debris-filled mucus into the large airways, allowing the debris to be coughed out of the body. When the cilia do not work properly, the body cannot rid itself of debris and is left vulnerable to serious infections in the sinuses, ears, and lungs. Over time, repeated infections can lead to scarring and permanent obstruction of these body areas. This study will determine when PCD starts and how it changes over time, specifically in terms of how well the lungs work, what germs grow in lung secretions, and how the lungs look on CT scans. This research may lead to a better understanding of PCD and thereby help doctors improve clinical management of the disease.

Children in this study will attend six study visits over 5 years. At the first visit, parents will review their child's medical and cough history with doctors. Also at this visit, children will undergo a physical exam that will include measures of temperature, blood pressure, heart rate, respiration rate, and oxygen saturation level. Additional procedures will include collection of a respiratory mucus sample or a throat culture, measurement of nasal nitric oxide, collection of blood and urine for specimen banking, a CT scan, and lung function testing. Children younger than 3 years of age will undergo the scan and lung function test under sedation. Children older than 3 years of age will not receive sedation. CT scans will be performed at the initial visit and during the visits 3 and 5 for children older than 3. For children younger than 3 years, chest CT scans will be performed at the initial visit and during visits 4 and 6. Lung function tests and blood and urine collection may be repeated at some of the remaining yearly visits. Between yearly visits, parents will track on a calendar their children's use of oral, inhaled, and intravenous antibiotics.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

Approximately 2 teaspoons of blood and a small amount of urine (if the child is able to urinate in a cup) will be collected and held at the specimen bank located at Denver Children's Hospital. These samples will be used to help identify markers that may predict the clinical course of PCD.

Non-Probability Sample

Participants in this study will be children younger than 5 years of age who have been diagnosed with PCD as based on electron microscopy and/or presence of two known disease-causing gene mutations or for whom a diagnosis of PCD has been determined probable as based on clinical features and very low nasal nitric oxide (less than 60 nl/minute).

Kartagener Syndrome
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
48
July 2015
July 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Younger than 5 years of age
  • Diagnosis of PCD or probable PCD based on criteria listed above
  • Parent or legal guardian willing to give informed consent

Exclusion Criteria:

  • Unable to attend follow-up appointments
  • History of lung transplant
  • Any co-existing severe diseases that may have significant impact on lung function, respiratory infections, or overall health status (i.e., severe congenital heart disease, severe scoliosis, AIDS, cancer, or end-stage kidney disease)
Both
up to 4 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
 
NCT00722878
RDCRN 5903, 9-U54-HL096458
Yes
Margaret Leigh, MD, University of North Carolina, Chapel Hill
University of North Carolina, Chapel Hill
National Heart, Lung, and Blood Institute (NHLBI)
Study Chair: Margaret W. Leigh, MD University of North Carolina, Chapel Hill
Study Chair: Margaret Rosenfeld, MD, MPH Seattle Children's Hospital
University of North Carolina, Chapel Hill
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP